In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Thymogen (oglufanide) | Mixture Thymalin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Mixture | |
| Area | Immune and antimicrobial | Immune and antimicrobial | |
| Evidence | |||
| Amount of evidence | 123 | 242 (plus 20 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 4 (3 in people) | 4 (3 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 3 | None registered | |
Shared outcomes
From the regulatory data of each peptide.
No FDA approval and no central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Thymogen (oglufanide) | Thymalin |
|---|---|---|
| Immune responseImmune and inflammation | 54112518 | 107 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
| Infection and antimicrobial activityRespiratory | 853 | 734 |
|---|
| Receptor activity and mechanismNervous system and cognition | 853 | 252212 |
|---|
| MortalityWhole body | 11110 | 835 |
|---|
| Inflammation markersImmune and inflammation | 22 | 9513 |
|---|
| Adverse eventsWhole body | 541 | 11 |
|---|
| Wound healingSkin and wound | 514 | 22 |
|---|
| Tumor growthCancer | 99 | 55 |
|---|
| Overall treatment effectWhole body | 22 | 211 |
|---|
| Intensive care and hospital outcomesWhole body | 11 | 11 |
|---|
| Aging markersAging and longevity | 22 | 11 |
|---|
| Cognition and memoryNervous system and cognition | 11 | 55 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
3 trials · 1 completed · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)
University of Southern California18 participantsNov 1999 to Nov 2001
Colorectal Cancer
CytranStart Jan 2001
Ovarian Cancer · Primary Peritoneal Cavity Cancer
University of Southern California43 participantsFeb 1999 to Aug 2001
Ovarian Cancer
No registered trial that tests Thymalin found in ClinicalTrials.gov.